Recently, Axiata Biotechnology, a developer and manufacturer of biomedical consumables, completed an A+ round of financing of nearly 100 million yuan. This round of financing was led by Qiandao Fund and followed by Borun Capital.
It is understood that this round of financing will be mainly used to expand the company’s high-end product pipeline, research and development of raw materials and material modifications, provide leading consumable CDMO services, and build a full range of international channels.
In August 2022, Axiata Biotechnology received nearly 100 million yuan in Series A financing from Apricot Capital, Wuxi Guolian Innovation, Borun Capital, and Zhejiang Hongshi.
Suzhou Yatong Biomedical Technology Co., Ltd. was established in November 2020. It is a company that mainly focuses on the design, research and development, production and sales of high-end consumables and packaging materials in the fields of life sciences, agricultural and animal husbandry sciences, medical diagnosis, and drug research and development, and provides related A high-tech enterprise providing overall solutions for consumables and CDMO services. Against the background of the rapid development of the global biotechnology industry and domestic substitution, the core management team relied on solid product development and production management experience to quickly complete the industry’s leading automation consumable production process and CDMO service system, comprehensively covering biochemistry, immunity, Molecule, POCT testing and consumable product categories for production have rapidly expanded and entered the domestic mainstream medical customer supplier system; at the same time, with the blessing of the team’s global vision, the company has forward-looking layout and entered many countries in Europe, America, Southeast Asia, the Middle East and Africa. The customer system in several countries ensures that the company actively participates in international market competition and lays a solid foundation for further leading domestic consumables to go overseas.
According to different life science application scenarios, laboratory plastic consumables can be roughly divided into: molecular biology, cell biology, filtration/purification, carrier/storage, diagnosis, drug research and development, agricultural and animal husbandry science consumables, etc. The company has accumulated nearly 20 years of experience in molds, production processes, raw material formulas, intelligent production, and full-process quality control. With the gradual improvement of R&D capabilities, the company continues to increase investment in R&D in the field of raw materials and formulas, and gathers materials. R&D related talents have gradually reached or even surpassed internationally renowned brands in terms of consumable performance, laying a solid foundation for providing customers with better consumable CDMO services. The main raw materials are high molecular polymers with certain biocompatibility, including: highly transparent plastic materials (polystyrene PS, polymethylmethacrylate PMMA, polycarbonate PC, etc.), common plastics (polypropylene PP , polyethylene (PE, polyethylene terephthalate (PET)), engineering plastics (ABS plastic, nylon PA, polyformaldehyde POM), etc., according to different product performance and application scenarios, increase the research and development of additives and formulas based on raw materials. Gradually realize domestic substitution of high-value consumables and high-quality CDMO services for consumables, and make breakthroughs in subdivided fields such as microfluidics, chemiluminescence, second-generation sequencing, POCT, agricultural breeding, and medical auxiliary materials.
Medical polymer plastic consumables usually have strict requirements on the material surface’s characteristics such as hydrophilic/hydrophobic, protein-philic/phobic, nucleic acid-philic/phobic, antistatic, biocompatibility, light transmittance, and temperature-sensitive response. There are technical barriers to raw materials and product production. High, has always been a bottleneck in my country’s life sciences industry. The global biomedical industry continues to expand, providing fertile soil for the rapid development of the industry. There are a few domestic companies whose design, manufacturing and production processes have reached internationally advanced levels. With the rapid development of the industry, industrial upgrading and integration are accelerated. Yatong Biotechnology is a high-end consumables CDMO company with capabilities in self-research of molds, raw material research and development, and international market deployment. It has implemented a full-process automated production line, 100,000-level, 10,000-level and 100-level GMP injection molding production workshops, and will continue to expand in the future. product lines and customized product categories to provide customers in related fields with high-quality, quick response, and stable supply of products and services.
微信扫一扫打赏
